CD8A and neoplasm: Despite the ability of vaccines and immunotherapies to reproducibly augment circulating levels of CD8+ T cells reactive against tumor-associated antigens (TAA) in the peripheral blood of patients, rates for objective clinical responses in these trials have been disappointingly modest (8).